AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), DEEPSEEK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History & Presentation (Timestamp: 1 Week Prior to Admission - Monsoon Season)
A 54-year-old female consultant residing in Thrissur,Kerala presents to the emergency department with a 1-week history of rapidly progressive ascending lower extremity weakness, high-grade fevers, a generalized non-itchy skin rash, and diplopia.
HPI: Symptoms began 7 days prior with bilateral hip pain and a feeling of an unsteady gait. On the morning of admission, she attempted to step out of bed, collapsed onto the floor, and was completely unable to move her legs. Over the preceding 24 hours, she developed high-grade fevers (38.8–39°C), nausea, vomiting, binocular diplopia, and acute urinary retention requiring a Foley catheter.
Environmental & Exposure History: Works from home, keeps a pet cat. No recent domestic or international travel, no outdoor hiking. However, her household experienced a severe mosquito infestation during the peak monsoon season, resulting in multiple mosquito bites.
PMH / Meds: Estradiol 0.1mg patch, Progesterone 200mg. No chronic medical conditions.
Social History: Non-smoker, no alcohol or illicit drug use, no high-risk sexual exposures or sick contacts.

Resident:

Hello, Chief Resident here.

Key Findings: A 54-year-old female in Kerala presents during peak monsoon with acute ascending lower extremity paralysis, urinary retention, binocular diplopia, high-grade fevers, and a non-itchy rash following significant mosquito exposure.

Differential Diagnoses:
1. Flavivirus Neuroinvasive Disease (e.g., West Nile / Dengue Myelitis) (45%): High-risk endemic exposure presenting with acute flaccid paralysis (anterior horn cell involvement), brainstem dysfunction, fever, and rash.
2. Acute Disseminated Encephalomyelitis (ADEM) / Autoimmune Myelitis (25%): Rapidly progressive spinal cord and brainstem neuroinflammation following a febrile viral prodrome.
3. Guillain-Barré Syndrome (GBS) / Miller Fisher Variant (15%): Ascending flaccid paraplegia, autonomic dysfunction, and diplopia, though high fevers and rash are atypical.
4. Scrub Typhus / Leptospirosis Neuro-Involvement (15%): Endemic monsoon zoonoses capable of producing high fever, rash, and acute radiculomyelitis.

Recommended Prioritized Tests:
1. MRI Brain and Spine (Whole) with contrast: Assess for transverse myelitis, brainstem lesions, or anterior horn enhancement.
2. Lumbar Puncture (CSF Analysis): Pleocytosis, protein, glucose, and viral/bacterial PCR.
3. CSF & Serum Arbovirus Panel: West Nile Virus, Dengue, and Japanese Encephalitis IgM/PCR.
4. Scrub Typhus IgM & Leptospira MAT/PCR.
5. Serum AQP4-IgG and MOG-IgG antibodies: Rule out NMOSD/MOGAD.

Attending:

Take their next turn by giving slightly improved recommendations
You are an expert Attending Consultant.
Critique or suggest improvements to the clinical plan proposed by the Chief Resident.
Give your top 3 Differential diagnosies.
Be concise. Use technical language and a high insight-to-word ratio.
Suggest 5-7 specific points if any.
Limit ur response to less than 200 words.
Always start your dialogue by saying: "Hello Attending Consultant here"

Expert:

Attending: Hello Attending Consultant here.

Good framework, but the plan is missing the key diagnostic pivot: distinguishing anterior horn cell disease from acute demyelinating neuropathy. Concurrent high fever at paralysis onset argues strongly against classic post-infectious GBS (patients are typically afebrile when weakness begins).

Top 3 Differentials:
1. West Nile Virus neuroinvasive disease – Fever + rash + acute flaccid paralysis is the classic triad; WNV is endemic/outbreak-prone in Kerala. Brainstem involvement explains diplopia.
2. Dengue-associated neuromyelitis/myositis – Monsoon hyperendemic; causes myelitis, GBS, and myopathic weakness.
3. Zika virus infection – Rash + GBS association; prior Kerala outbreaks.

Specific Improvements:
1. Urgent EMG/NCS – Motor axonal pattern with normal sensory studies = anterior horn (flavivirus); demyelination = GBS. This single test redirects management.
2. Add Zika PCR + Dengue NS1 to the arboviral panel; NS1 still useful at day 7 alongside paired IgM/IgG.
3. Send CSF WNV IgM – More sensitive than serum in early neuroinvasive disease.
4. Respiratory surveillance (FVC/NIF q6h) – Diaphragmatic failure is the killer in both WNV-AFP and GBS; low ICU threshold.
5. MRI caveat: Expect only ventral horn "owl's eye" T2 signal or normal imaging early – don't let a negative MRI falsely reassure.
6. Hold empiric IVIG/steroids until EMG/CSF clarify GBS vs infectious myelitis.
7. Check CK (dengue myositis) and notify public health – arboviral cases are reportable.

Round 2

User:

Stage 2: Physical Examination & Clinical Findings (Timestamp: Admission / Day 1)
Physical Exam: T 38.8°C (spiking daily to 39°C), HR 92 bpm, BP 125/67 mmHg, RR 18/min, SpO2 100% room air. Patient is lying in bed, febrile, in moderate discomfort.
Cutaneous Exam: Diffuse, non-pruritic, blanching morbilliform maculopapular exanthem covering the chest, abdomen, upper extremities, and lower extremities, with sparse petechiae; spares the palms and soles.
Neurologic Exam: Alert, oriented x 4. Cranial nerves intact; visual fields and extraocular movements intact on bedside testing (intermittent diplopia reported).
Motor Strength: Upper extremities 5/5 bilaterally; marked abdominal wall weakness (4/5); Lower Extremities 4/5 proximally with rapid distal weakness (2-3/5), rendering her completely unable to stand or walk.
Reflexes & Sensation: Deep tendon reflexes 2+ throughout (patellar, Achilles, biceps). Proprioception intact; mildly reduced vibratory sensation in bilateral lower extremities below knees.

Resident:

Hello, Chief Resident here.

Updated Key Findings: Persistent high fever (38.8–39°C), morbilliform rash with sparse petechiae, trunk/abdominal wall weakness, and progressive lower-extremity paresis with preserved deep tendon reflexes (2+). Preserved DTRs strongly favor spinal cord/anterior horn disease over classic peripheral demyelinating GBS.

Differential Diagnoses:
1. West Nile Neuroinvasive Disease (55%): High-risk monsoon exposure, persistent fever, rash, and anterior horn cell/myelitis presentation with preserved DTRs.
2. Dengue-Associated Myelitis (25%): Hyperendemic in Kerala; rash with petechiae, fever, and acute spinal cord/radicular motor deficits.
3. Scrub Typhus / Leptospirosis Neuro-Involvement (10%): Endemic monsoon zoonoses presenting with high fever, rash, and radiculomyelitis.
4. Acute Disseminated Encephalomyelitis (ADEM) / Myelitis (10%): Acute neuroinflammation, though ongoing daily high fevers argue strongly for direct viral neuroinvasion.

Recommended Prioritized Tests:
1. Urgent Whole Spine & Brain MRI: Assess for acute transverse myelitis or anterior horn "owl's eye" T2 signal.
2. EMG/NCS: Distinguish anterior horn cell disease from neuropathic processes.
3. Lumbar Puncture: CSF cell count, protein, glucose, plus WNV, Dengue, Zika, and JE IgM/PCR.
4. Serologies: Dengue NS1/IgM, WNV IgM, Scrub Typhus IgM, Leptospira MAT.
5. Respiratory Surveillance: Serial FVC/NIF every 6 hours.

Attending:

-networkthinkingReading the history and physical exam findings, the key new information is the preserved deep tendon reflexes (2+) in the setting of significant lower extremity weakness. This is a critical clinical finding that strongly argues against Guillain-Barré syndrome, where areflexia is a hallmark. The presence of high fevers, rash with petechiae, and preserved reflexes points toward a spinal cord or anterior horn cell process rather than a peripheral neuropathy.

The Chief Resident's differential and plan are reasonable but could be more focused. The top differential should indeed be West Nile neuroinvasive disease given the classic triad of fever, rash, and acute flaccid paralysis with preserved reflexes. Dengue is also high on the list given the petechial rash and endemicity. The plan should emphasize the urgency of EMG/NCS to confirm anterior horn cell involvement and the need for specific serological testing.

I'll structure my response to first acknowledge the key finding, then refine the differential, and finally provide specific, actionable improvements to the plan, keeping it concise and technical.Hello Attending Consultant here.

The preserved deep tendon reflexes (2+) in the setting of profound distal weakness is the pivotal finding. This effectively rules out classic GBS and strongly localizes the pathology to the spinal cord (anterior horn cells) or muscle, making a central or myopathic process far more likely than a peripheral neuropathy.

Top 3 Differentials:
1. West Nile Virus Neuroinvasive Disease: The triad of persistent high fever, morbilliform/petechial rash, and acute flaccid paralysis with preserved reflexes is pathognomonic.
2. Dengue-Associated Myelitis/Myositis: The petechial component of the rash in a hyperendemic zone makes this a very strong contender.
3. Enterovirus D68/A71 Myelitis: Can mimic WNV with anterior myelitis and brainstem involvement, though rash is less typical.

Specific Plan Improvements:
1. Prioritize EMG/NCS immediately: This is now the highest-yield test. A pure motor axonal loss pattern with normal sensory studies confirms anterior horn cell disease (e.g., WNV) and directs management away from IVIG/plasmapheresis.
2. Add Serum Creatine Kinase (CK): Essential to rule out a primary myositic component, which is common in dengue and would alter management.
3. Refine CSF Analysis: Send for WNV IgM, Dengue NS1/PCR, and Enterovirus PCR. A neutrophilic pleocytosis can be an early clue for WNV.
4. MRI Caveat: A negative spine MRI does not exclude anterior horn cell disease; the "owl's eye" sign may appear late or be subtle.
5. Strict Respiratory Monitoring: Initiate serial FVC/NIF q4h. Diaphragmatic paralysis from cervical anterior horn cell involvement is the primary cause of mortality.
6. Hold Immunomodulatory Therapy: Do not start IVIG or steroids until EMG/CSF results clarify an infectious versus autoimmune etiology.

Expert:

Attending: -networkthinkingReading the user's prompt, the task is to critique the Chief Resident's plan as an Attending Consultant. The key is to refine the differential diagnosis based on the new clinical data and suggest specific, high-yield improvements to the diagnostic and management plan.

First, I'll analyze the new physical exam findings. The most critical finding is the presence of preserved deep tendon reflexes (2+) in a patient with significant lower extremity weakness. This is a major pivot point. Classic Guillain-Barré Syndrome (GBS) presents with areflexia or hyporeflexia. Preserved reflexes strongly argue against a peripheral demyelinating process like GBS and point towards a pathology at the level of the spinal cord (myelopathy) or muscle (myopathy).

Given this, the differential diagnosis needs to be re-ranked:
1. West Nile Neuroinvasive Disease: This moves to the top spot. The combination of high fever, rash, and acute flaccid paralysis with preserved reflexes is the classic presentation of WNV myelitis/anterior horn cell disease.
2. Dengue-Associated Myelitis/Myositis: The petechial rash in a dengue-endemic area makes this a very strong contender. The weakness could be from spinal cord inflammation or direct muscle involvement.
3. Enterovirus D68/A71 Myelitis: These viruses can cause an identical syndrome of acute flaccid myelitis, often with a preceding febrile illness.

The Chief Resident's plan is good, but I can make it more precise and urgent. Here are my specific points of improvement:

  1. Prioritize EMG/NCS: This is now the single most important test. It will definitively distinguish an anterior horn cell process (motor axonal loss, normal sensory) from a myopathy (myopathic units, normal sensory) or a peripheral neuropathy. This result directly impacts treatment decisions.
  2. Add Serum Creatine Kinase (CK): A simple blood test that is crucial. A very high CK would suggest a primary myositis (like in dengue), while a normal or mildly elevated CK would support a neuropathic/anterior horn process.
  3. Refine CSF and Serum Testing: I should specify the exact tests. For CSF: WNV IgM, Dengue NS1/PCR, and Enterovirus PCR. For serum: paired acute/convalescent arboviral serologies are key.
  4. Management - Respiratory Monitoring: I need to emphasize the importance of serial FVC/NIF monitoring every 4-6 hours. Diaphragmatic weakness from cervical cord involvement is a life-threatening complication.
  5. Management - Withhold Immunotherapy: It's critical to state that IVIG or steroids should be held until an infectious etiology is reasonably excluded or a clear autoimmune one is identified, as these can be harmful or ineffective in viral infections.

I'll structure my response to be concise, starting with the key clinical insight, then the re-ranked differential, and finally the specific, actionable recommendations.Hello Attending Consultant here.

The preserved deep tendon reflexes (2+) in the setting of profound distal weakness is the pivotal finding. This effectively rules out classic GBS and strongly localizes the pathology to the spinal cord (anterior horn cells) or muscle, making a central or myopathic process far more likely than a peripheral neuropathy.

Top 3 Differentials:
1. West Nile Virus Neuroinvasive Disease: The triad of persistent high fever, morbilliform/petechial rash, and acute flaccid paralysis with preserved reflexes is pathognomonic.
2. Dengue-Associated Myelitis/Myositis: The petechial component of the rash in a hyperendemic zone makes this a very strong contender.
3. Enterovirus D68/A71 Myelitis: Can mimic WNV with anterior myelitis and brainstem involvement, though rash is less typical.

Specific Plan Improvements:
1. Prioritize EMG/NCS immediately: This is now the highest-yield test. A pure motor axonal loss pattern with normal sensory studies confirms anterior horn cell disease (e.g., WNV) and directs management away from IVIG/plasmapheresis.
2. Add Serum Creatine Kinase (CK): Essential to rule out a primary myositic component, which is common in dengue and would alter management.
3. Refine CSF Analysis: Send for WNV IgM, Dengue NS1/PCR, and Enterovirus PCR. A neutrophilic pleocytosis can be an early clue for WNV.
4. MRI Caveat: A negative spine MRI does not exclude anterior horn cell disease; the "owl's eye" sign may appear late or be subtle.
5. Strict Respiratory Monitoring: Initiate serial FVC/NIF q4h. Diaphragmatic paralysis from cervical anterior horn cell involvement is the primary cause of mortality.
6. Hold Immunomodulatory Therapy: Do not start IVIG or steroids until EMG/CSF results clarify an infectious versus autoimmune etiology.

Round 3

User:

Stage 3: Initial Laboratory Evaluation & Neuroimaging (Timestamp: Hospital Days 1-2)
Laboratory Panel:
- Hemogram: WBC 6,600/µL (normal differential), Hb 14.6 g/dL, Platelets 139,000/µL (mild thrombocytopenia).
- Chemistry & LFTs: Normal BMP (Serum Creatinine 0.62 mg/dL), normal LFTs (AST 18 U/L, ALT 12 U/L), normal CK (107 U/L). Inflammatory markers low/normal (ESR 16 mm/hr, CRP 1.7 mg/L).
- Respiratory & Blood Cultures: Respiratory viral panel (COVID-19, Influenza, RSV) negative; blood cultures no growth.
Neuroimaging:
- CT Head & MRI Brain/Orbits (with contrast): Normal; no intracranial hemorrhage, brainstem lesions, or optic nerve enhancement.
- MRI Spine (Cervical, Thoracic, Lumbar with contrast): Demonstrates longitudinally extensive central gray matter T2 hyperintensity preferentially involving the anterior horn cells (anterior spinal cord motor neurons) extending through the thoracic cord and conus medullaris, with sparing of the posterior dorsal columns and absence of abnormal contrast enhancement (Acute Flaccid Myelitis / Poliomyelitis-like pattern).

Resident:

Hello, Chief Resident here.

Key Updated Findings:
Spine MRI reveals pathognomonic longitudinally extensive anterior horn cell T2 hyperintensity (poliomyelitis-like pattern), confirming Acute Flaccid Myelitis (AFM). Mild thrombocytopenia (139,000/µL) and normal CK rule out primary myositis, focusing diagnosis on viral anterior horn cell neuroinvasion.

Differential Diagnoses:
1. West Nile Virus Neuroinvasive Disease (65%): Classic triad of fever, rash, and poliomyelitis-like AFM with anterior horn cell predilection following mosquito exposure.
2. Other Arboviral Myelitis (Dengue / Japanese Encephalitis) (20%): Endemic in Kerala; presents with anterior spinal cord gray-matter involvement and mild thrombocytopenia.
3. Non-Polio Enterovirus (EV-D68 / EV-A71) Myelitis (10%): Primary viral cause of epidemic acute flaccid myelitis.
4. Autoimmune / Post-Infectious Myelitis (MOGAD/NMOSD) (5%): Can cause gray-matter restricted cord lesions, though ongoing daily high fevers favor direct viral neuroinvasion.

Recommended Prioritized Tests:
1. CSF Analysis & Arboviral Panel: CSF cell count, protein, WNV IgM/PCR, Dengue NS1/IgM, JE IgM, and Enterovirus PCR.
2. Serum Flavivirus Serologies: WNV, Dengue, and JE IgM/IgG.
3. EMG/NCS: Confirm pure motor axonal anterior horn cell localization.
4. Serial Respiratory Surveillance: Monitor FVC and NIF every 4 hours.
5. Serum AQP4-IgG and MOG-IgG: Rule out autoimmune neuroinflammation.

Attending:

Hello Attending Consultant here.

The MRI pattern of longitudinally extensive anterior horn cell T2 hyperintensity without enhancement is pathognomonic for viral acute flaccid myelitis. The mild thrombocytopenia, petechial rash, and monsoon mosquito exposure elevate dengue and WNV as the prime suspects.

Top 3 Differentials:
1. West Nile Virus neuroinvasive disease – classic poliomyelitis-like AFM with fever and rash.
2. Dengue-associated myelitis – thrombocytopenia and petechial rash are key clues; anterior horn tropism is reported.
3. Enterovirus D68/A71 myelitis – epidemic AFM, though rash and thrombocytopenia are atypical.

Specific Plan Improvements:
1. CSF as urgent priority: Send WNV IgM, Dengue NS1/PCR, and Enterovirus PCR. A CSF neutrophilic pleocytosis can be an early WNV clue.
2. Add serum Dengue NS1 antigen – still detectable at day 7–8 of illness, more sensitive than IgM alone.
3. Defer EMG/NCS – MRI already localizes to anterior horn cells; EMG adds prognostic value but does not alter acute management. Perform later for baseline.
4. Withhold all immunomodulation – no IVIG, steroids, or PLEX. The non-enhancing lesion indicates direct viral cytotoxicity, not post-infectious inflammation.
5. Aggressive respiratory monitoring – serial FVC/NIF q4h; low threshold for elective intubation if FVC <15 mL/kg or declining.
6. Notify public health immediately – suspected arboviral AFM is reportable and triggers vector-control measures.
7. Add Zika virus PCR/IgM to arboviral panel given prior Kerala outbreaks and similar AFM-GBS spectrum.

Expert:

Attending: Hello Attending Consultant here.

The MRI pattern of longitudinally extensive anterior horn cell T2 hyperintensity without enhancement is pathognomonic for viral acute flaccid myelitis. The mild thrombocytopenia, petechial rash, and monsoon mosquito exposure elevate dengue and WNV as the prime suspects.

Top 3 Differentials:
1. West Nile Virus neuroinvasive disease – classic poliomyelitis-like AFM with fever and rash.
2. Dengue-associated myelitis – thrombocytopenia and petechial rash are key clues; anterior horn tropism is reported.
3. Enterovirus D68/A71 myelitis – epidemic AFM, though rash and thrombocytopenia are atypical.

Specific Plan Improvements:
1. CSF as urgent priority: Send WNV IgM, Dengue NS1/PCR, and Enterovirus PCR. A CSF neutrophilic pleocytosis can be an early WNV clue.
2. Add serum Dengue NS1 antigen – still detectable at day 7–8 of illness, more sensitive than IgM alone.
3. Defer EMG/NCS – MRI already localizes to anterior horn cells; EMG adds prognostic value but does not alter acute management. Perform later for baseline.
4. Withhold all immunomodulation – no IVIG, steroids, or PLEX. The non-enhancing lesion indicates direct viral cytotoxicity, not post-infectious inflammation.
5. Aggressive respiratory monitoring – serial FVC/NIF q4h; low threshold for elective intubation if FVC <15 mL/kg or declining.
6. Notify public health immediately – suspected arboviral AFM is reportable and triggers vector-control measures.
7. Add Zika virus PCR/IgM to arboviral panel given prior Kerala outbreaks and similar AFM-GBS spectrum.

Round 4

User:

Stage 4: Lumbar Puncture & Empiric Immunotherapy (Timestamp: Hospital Days 2-4)
Lumbar Puncture Results:
- Opening Pressure: Normal.
- CSF Chemistry: Glucose 48 mg/dL (normal), Protein elevated at 87 mg/dL.
- CSF Cell Count: Nucleated Cell Count 88 cells/µL (85% Lymphocytes, 15% PMNs), RBC 2 cells/µL.
Working Differential in Neuro-ICU: Transverse Myelitis vs. Acute Flaccid Myelitis (AFM) vs. Neuromyelitis Optica Spectrum Disorder (NMOSD / anti-AQP4 / anti-MOG) vs. Neuroinvasive Viral Encephalomyelitis.
Empiric Management: Initiated on high-dose pulse IV Methylprednisolone (1g daily x 5 days) combined with Therapeutic Plasma Exchange (PLEX x 5 sessions) for presumed autoimmune transverse myelitis / NMOSD while viral and serologic panels remained pending.
Clinical Response: Showed gradual stabilization of upper limb and trunk strength during PLEX.

Resident:

Hello, Chief Resident here.

Key Updated Findings: CSF demonstrates a lymphocytic pleocytosis (88 cells/µL, 85% lymphocytes) and elevated protein (87 mg/dL). Clinical stabilization occurred during empiric IV Methylprednisolone and PLEX.

Differential Diagnoses:
1. West Nile Virus Neuroinvasive Disease (50%): Predilection for anterior horn cells on MRI, mosquito exposure, fever, rash, and lymphocytic CSF; stabilization may reflect natural disease plateau.
2. Dengue / Arboviral Myelitis (25%): Endemic in Kerala; aligns with fever, rash, mild thrombocytopenia, and viral CSF profile.
3. Autoimmune Myelitis (NMOSD / MOGAD) (15%): Longitudinally extensive cord involvement and stabilization with PLEX/steroids, though ongoing high fevers favor an infectious etiology.
4. Enterovirus (EV-D68/A71) Myelitis (10%): Viral cause of acute flaccid myelitis with lymphocytic pleocytosis.

Recommended Prioritized Tests:
1. CSF & Serum Arboviral Panel: WNV IgM, Dengue NS1/IgM/PCR, Zika, and JE serology.
2. CSF Enterovirus PCR.
3. Serum & CSF AQP4-IgG and MOG-IgG (cell-based assays).
4. Serial Respiratory Surveillance: FVC and NIF monitoring every 6 hours.
5. EMG/NCS: Assess degree of motor axonal loss and anterior horn cell involvement.

Attending:

<|begin▁of▁sentence|># Attending Consultant Response

Hello Attending Consultant here.

The CSF lymphocytic pleocytosis with elevated protein is consistent with viral meningoencephalitis, but the empiric decision to initiate dual immunotherapy (steroids + PLEX) is premature and potentially harmful. The non-enhancing anterior horn cell lesion on MRI strongly argues against NMOSD/MOGAD, where enhancement is typical. Clinical stabilization during PLEX likely reflects the natural plateau of viral illness rather than treatment effect.

Top 3 Differentials:
1. West Nile Virus neuroinvasive disease – lymphocytic CSF with anterior horn cell tropism is classic.
2. Dengue-associated myelitis – thrombocytopenia and petechial rash support this.
3. Enterovirus D68/A71 myelitis – epidemic AFM with similar CSF profile.

Specific Plan Improvements:
1. Immediately discontinue PLEX and steroids – immunosuppression in active viral neuroinvasive disease risks worsening viral replication. The non-enhancing MRI lesion indicates direct viral cytotoxicity, not autoimmune inflammation.
2. Expedite CSF WNV IgM and Dengue NS1/PCR – these results should have been available before initiating immunotherapy. Lymphocytic pleocytosis with elevated protein is the expected CSF profile for both.
3. Send CSF for viral metagenomic next-generation sequencing (mNGS) – if standard panels are negative, this can identify rare arboviruses or enteroviruses.
4. Monitor for PLEX complications – check fibrinogen, platelets, and immunoglobulin levels; PLEX can worsen thrombocytopenia and coagulopathy.
5. Maintain strict respiratory monitoring – clinical stabilization may be temporary; diaphragmatic involvement can still evolve.
6. Do not escalate immunotherapy – if no improvement occurs after stopping PLEX/steroids, this further supports viral etiology and avoids unnecessary immunosuppression.
7. Consult infectious disease and neurology jointly – management of viral AFM requires coordinated supportive care, not immunomodulation.

Expert:

Attending: Hello Attending Consultant here.

The CSF lymphocytic pleocytosis with elevated protein is consistent with viral meningoencephalitis, but the empiric decision to initiate dual immunotherapy (steroids + PLEX) is premature and potentially harmful. The non-enhancing anterior horn cell lesion on MRI strongly argues against NMOSD/MOGAD, where enhancement is typical. Clinical stabilization during PLEX likely reflects the natural plateau of viral illness rather than treatment effect.

Top 3 Differentials:
1. West Nile Virus neuroinvasive disease – lymphocytic CSF with anterior horn cell tropism is classic.
2. Dengue-associated myelitis – thrombocytopenia and petechial rash support this.
3. Enterovirus D68/A71 myelitis – epidemic AFM with similar CSF profile.

Specific Plan Improvements:
1. Immediately discontinue PLEX and steroids – immunosuppression in active viral neuroinvasive disease risks worsening viral replication. The non-enhancing MRI lesion indicates direct viral cytotoxicity, not autoimmune inflammation.
2. Expedite CSF WNV IgM and Dengue NS1/PCR – these results should have been available before initiating immunotherapy. Lymphocytic pleocytosis with elevated protein is the expected CSF profile for both.
3. Send CSF for viral metagenomic next-generation sequencing (mNGS) – if standard panels are negative, this can identify rare arboviruses or enteroviruses.
4. Monitor for PLEX complications – check fibrinogen, platelets, and immunoglobulin levels; PLEX can worsen thrombocytopenia and coagulopathy.
5. Maintain strict respiratory monitoring – clinical stabilization may be temporary; diaphragmatic involvement can still evolve.
6. Do not escalate immunotherapy – if no improvement occurs after stopping PLEX/steroids, this further supports viral etiology and avoids unnecessary immunosuppression.
7. Consult infectious disease and neurology jointly – management of viral AFM requires coordinated supportive care, not immunomodulation.

Round 5

User:

Stage 5: Final Unifying Diagnosis & Serologic Confirmation (Timestamp: Discharge / Follow-up)
Microbiologic & Serologic Panel Results:
- CSF West Nile Virus IgM antibody: STRONGLY POSITIVE.
- Serum WNV IgM positive.
- Autoimmune Encephalitis Panel, anti-AQP4 (NMO), anti-MOG, Enterovirus PCR, HSV/VZV PCR, Lyme, Syphilis, and fungal/bacterial CSF cultures all negative.
Final Unifying Diagnosis: Neuroinvasive West Nile Virus (WNV) Encephalomyelitis / Acute Flaccid Paralysis (WNV Poliomyelitis-like Syndrome) presenting with anterior horn cell myelitis, morbilliform exanthem, high-grade fever, and neurogenic urinary retention.
Course & Outcome: PLEX was discontinued upon confirmation of WNV. Transferred to acute neuro-rehabilitation, where she regained upper body and partial lower extremity motor function, experiencing transient painful neuropathic dysesthesias in lower limbs during axonal re-innervation.

Resident:

Hello, Chief Resident here.

Key Findings: Definitive confirmation of Neuroinvasive West Nile Virus (WNV) Encephalomyelitis / Poliomyelitis-like Syndrome based on strongly positive CSF and serum WNV IgM antibodies, correlating with the classic clinical triad of fever, morbilliform rash, and MRI-proven anterior horn cell myelitis.

Final Diagnosis & Probabilities:
1. Neuroinvasive West Nile Virus Poliomyelitis-like Syndrome (100%): Confirmed via CSF/serum WNV IgM serology, supported by monsoon mosquito exposure, selective motor neuron tropism, and negative autoimmune/alternative infectious workup.

Prioritized Management & Next Steps:
1. Neuropathic Pain Management: Initiate gabapentinoids (e.g., pregabalin or gabapentin) or duloxetine for lower extremity re-innervation dysesthesias.
2. Intensive Neuro-Rehabilitation: Focused physical and occupational therapy alongside neuro-urologic monitoring to assist in bladder weaning.
3. Public Health Notification: Mandatory report to local Kerala public health authorities for vector surveillance and control.
4. Follow-up EMG/NCS (3–6 months): Assess the degree of permanent motor axonal loss and track peripheral re-innervation.
5. Avoid Immunosuppression: Confirm complete discontinuation of steroids/PLEX to prevent delayed viral clearance or secondary complications.

Attending:

<|begin▁of▁sentence|># Attending Consultant Response

Hello Attending Consultant here.

The serologic confirmation of WNV neuroinvasive disease validates the clinical and radiographic picture. The key learning point here is that the non-enhancing anterior horn cell lesion on MRI, combined with lymphocytic CSF pleocytosis, was pathognomonic for viral AFM and should have precluded empiric immunotherapy. The transient improvement during PLEX was almost certainly coincidental with the natural disease plateau.

Top 3 Differentials (Retrospective):
1. WNV poliomyelitis-like syndrome – confirmed.
2. Dengue-associated myelitis – excluded by serology.
3. Enterovirus D68/A71 myelitis – excluded by PCR.

Specific Management Recommendations:
1. Neuropathic pain protocol: Start gabapentin 100-300mg TID, titrating to effect. Tricyclic antidepressants (nortriptyline) are second-line. Avoid opioids given risk of respiratory depression in recovering neuromuscular disease.
2. Bladder management: Twice-daily bladder scans with intermittent catheterization protocol; urodynamic studies if retention persists beyond 4 weeks.
3. Respiratory surveillance: Continue serial FVC monitoring even during rehabilitation; late diaphragmatic weakness can occur.
4. Prognostic counseling: Only 30-50% of WNV AFP patients regain independent ambulation. Set realistic expectations for prolonged recovery over 6-12 months.
5. WNV serology caveat: IgM can persist >12 months; future febrile illnesses should not be misattributed to recurrent WNV without confirmatory PCR or seroconversion.
6. Long-term follow-up: Neurology and PM&R joint clinic at 3, 6, and 12 months to monitor motor recovery and manage spasticity that may emerge during re-innervation.
7. Public health reporting: Ensure formal notification to district surveillance unit for mosquito control interventions in the patient's residential area.

Expert:

Attending: Hello Attending Consultant here.

The serologic confirmation of WNV neuroinvasive disease validates the clinical and radiographic picture. The key learning point here is that the non-enhancing anterior horn cell lesion on MRI, combined with lymphocytic CSF pleocytosis, was pathognomonic for viral AFM and should have precluded empiric immunotherapy. The transient improvement during PLEX was almost certainly coincidental with the natural disease plateau.

Top 3 Differentials (Retrospective):
1. WNV poliomyelitis-like syndrome – confirmed.
2. Dengue-associated myelitis – excluded by serology.
3. Enterovirus D68/A71 myelitis – excluded by PCR.

Specific Management Recommendations:
1. Neuropathic pain protocol: Start gabapentin 100-300mg TID, titrating to effect. Tricyclic antidepressants (nortriptyline) are second-line. Avoid opioids given risk of respiratory depression in recovering neuromuscular disease.
2. Bladder management: Twice-daily bladder scans with intermittent catheterization protocol; urodynamic studies if retention persists beyond 4 weeks.
3. Respiratory surveillance: Continue serial FVC monitoring even during rehabilitation; late diaphragmatic weakness can occur.
4. Prognostic counseling: Only 30-50% of WNV AFP patients regain independent ambulation. Set realistic expectations for prolonged recovery over 6-12 months.
5. WNV serology caveat: IgM can persist >12 months; future febrile illnesses should not be misattributed to recurrent WNV without confirmatory PCR or seroconversion.
6. Long-term follow-up: Neurology and PM&R joint clinic at 3, 6, and 12 months to monitor motor recovery and manage spasticity that may emerge during re-innervation.
7. Public health reporting: Ensure formal notification to district surveillance unit for mosquito control interventions in the patient's residential area.

Top 15 Takeaways for Clinicians

  1. Classic Triad of WNV Neuroinvasive Disease: High fever, a non-pruritic trunk/limb morbilliform exanthem, and acute asymmetric flaccid paralysis during monsoon vector season is pathognomonic for West Nile Virus anterior horn cell myelitis.
  2. Selective Anterior Horn Cell Tropism: WNV targets the motor neurons of the anterior spinal cord, producing an Acute Flaccid Paralysis (AFP) syndrome clinically indistinguishable from poliovirus (WNV Poliomyelitis-like Syndrome).
  3. Preserved Reflexes Early in Disease: Unlike Guillain-Barré Syndrome (GBS) which presents with hyporeflexia or areflexia, viral anterior horn cell myelitis can present with preserved (2+) reflexes before extensive motor neuron cell death occurs.
  4. Radiologic Landmark of Viral AFM: Spine MRI characteristically demonstrates longitudinally extensive T2 hyperintensity restricted to the central gray matter (anterior horn cells / "owl's eye" sign) without contrast enhancement.
  5. Absence of Contrast Enhancement Signals Cytotoxicity: Non-enhancing anterior horn cell lesions indicate direct viral cytopathic destruction rather than post-infectious autoimmune demyelination (such as NMOSD or MOGAD).
  6. Harm of Empiric Immunosuppression in Active Viral Myelitis: Initiating high-dose corticosteroids or therapeutic plasma exchange (PLEX) in viral AFM is ineffective and potentially harmful by inhibiting viral clearance.
  7. Diagnostic Gold Standard: CSF WNV IgM antibody via ELISA is the primary diagnostic test for neuroinvasive WNV, as IgM does not cross the blood-brain barrier and indicates acute central nervous system infection.
  8. Limitations of Serum PCR and Serology: Serum WNV PCR is insensitive due to rapid transient viremia; however, serum WNV IgM is supportive and paired acute/convalescent serologies confirm diagnosis.
  9. Monsoon Vector Season Epidemiology: Arboviral neuroinvasive infections peak during monsoon/post-monsoon months (August–October) corresponding to Culex mosquito breeding cycles.
  10. Respiratory Surveillance for Diaphragmatic Weakness: Cervical cord or brainstem WNV involvement can cause diaphragmatic paralysis; serial monitoring of Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF) is essential.
  11. Management of Re-innervation Dysesthesias: As recovering motor axons re-innervate tissue, patients frequently experience painful burning neuropathic dysesthesias, which respond to gabapentinoids (pregabalin/gabapentin) or duloxetine.
  12. Long-Term Functional Prognosis: Motor recovery following WNV poliomyelitis-like paralysis is slow and often incomplete; only 30–50% of affected patients regain independent ambulation over 6–12 months.
  13. Persistence of CSF/Serum IgM Antibodies: WNV IgM antibodies can persist in serum and CSF for over 12 months, requiring cautious interpretation during subsequent febrile episodes.
  14. Public Health Reporting and Vector Control: Every confirmed or suspected case of WNV neuroinvasive disease mandates immediate notification to public health authorities for municipal mosquito control interventions.
  15. Multidisciplinary Rehabilitation Focus: Comprehensive management requires early physical, occupational, and neuro-urologic rehabilitation to manage neurogenic bladder, prevent joint contractures, and maximize functional independence.